Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIDME: Intravitreal Macugen for Ischaemic Diabetic Macular Oedema
2009-017540-13Phase 4Unknown
- Sponsor
- Clinical Trials and Research Governance
- Start
- Aug 2010
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegaptanib sodium in diabetic macular edema (DME), sponsored by Clinical Trials and Research Governance. Primary endpoint: Change in foveal avascular zone size at 30 weeks. Status: unknown.
02
Drugs
pegaptanib sodium
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2009-017540-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017540-13.